National Vision upgraded to Buy from Neutral at Citi

Citi upgraded National Vision (EYE) to Buy from Neutral with a price target of $21, up from $13. The company “checks several attractive boxes in the current environment” as it sells products that are non-discretionary, has mindshare for value, has self-help opportunities to improve sales, low tariff risk, its comps are accelerating, and it just reported a beat and raise quarter, the analyst tells investors in a research note. The firm says National Vision is a low-cost provider of a medical necessity with a strong track record of comping positively during economic cycles. It believes the stock’s risk/reward is favorable.